The PCSK9 Patent dispute saw a landmark UPC ruling that reinstated Amgen’s antibody patent, clarified core principles on inventive step, sufficiency, and claim interpretation, and strengthened legal certainty for innovators developing advanced biologic therapies across the European pharmaceutical & biopharmaceutical landscape.
This case highlights how the exenatide patent filed by Amylin Pharmaceuticals led to a detailed examination of inventive step, therapeutic efficacy, and Section 3(d) objections, culminating in a significant Delhi High Court judgment in Nov. 2025
In a landmark decision concerning SPC for Durvalumab, the District Court of The Hague upheld the Dutch Intellectual Property Office’s (IPO) refusal to grant a Supplementary Protection Certificate (SPC) for AstraZeneca’s cancer immunotherapy drug Durvalumab, marketed as Imfinzi®. Durvalumab is an anti-PD-L1 antibody used in treating various cancers, and the refusal of SPC status has … Read more
